Sign up to save your podcasts
Or
Share The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
We love to hear from our listeners. Send us a message.
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
Subscribe to the podcast!
Apple | Spotify | YouTube
View all episodes
By Erin Harris
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
Subscribe to the podcast!
Apple | Spotify | YouTube
More shows like Cell & Gene: The Podcast
View all
Nature Podcast
765 Listeners
Science Magazine Podcast
807 Listeners
Economist Podcasts
4,246 Listeners
Freakonomics Radio
32,043 Listeners
The Long Run with Luke Timmerman
124 Listeners
Immune
271 Listeners
The Readout Loud
318 Listeners
FT News Briefing
699 Listeners
Business Of Biotech
88 Listeners
BioCentury This Week
31 Listeners
Raising Health
147 Listeners
Biotech Hangout
11 Listeners
ASGCT Podcast Network
15 Listeners
Elon, Inc.
149 Listeners
Ground Truths
47 Listeners